An artificial blood vessel loaded with small molecule interfering RNA and its preparation method and application
Polydopamine coating was prepared by electrospinning and loaded with artificial blood vessels that interfere with RNA in small molecules. The cationic lipid nanoparticles modified by macrophage membrane inhibited the proliferation of vascular smooth muscle cells, solving the problem of small-diameter artificial blood vessel restenosis, realizing the simplification of the process and improvement of the effect.
Patent Information
- Application Number
- CN202410965546.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-07-18
AI Technical Summary
The existing small-diameter artificial blood vessels are prone to vascular restenosis due to endometrial hyperplasia, and the existing technology preparation process is complex or requires specific equipment, so there is a lack of effective clinical products.
Polydopamine-coated artificial blood vessels were prepared by electrospinning, and small molecules were loaded into interfering RNA through cationic lipid nanoparticles modified by macrophage membranes, bound to the blood vessel surface, and used charge and hydrogen bonding to inhibit the excessive proliferation of smooth muscle cells. .
It significantly improves the hydrophilicity and biocompatibility of blood vessels, reduces the engulfment of small molecules interferes with RNA, increases its release in target cells, effectively inhibits the proliferation of vascular smooth muscle cells, and solves the small-diameter artificial vascular restenosis. The problem is simple and efficient.
Smart Images

Figure CN118490891B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedical materials, and in particular to an artificial blood vessel loaded with small molecule interfering RNA, and a preparation method and application thereof. Background Art
[0002] The grafting technology generally refers to the restoration of blood flow by constructing a "bypass" vessel to bypass the narrowed or occluded blood vessel segment. It is widely used in clinical practice. It can not only build arteriovenous fistulas for kidney patients for dialysis treatment, but also be used to treat various ischemic diseases caused by vascular obstruction or stenosis, such as coronary artery bypass surgery and peripheral vascular bypass surgery. Autologous blood vessels are commonly used grafting vessels in clinical practice, such as the great saphenous vein and the internal mammary artery. However, the acquisition of autologous blood vessels often causes trauma to the patient's donor site, and if the blood vessels in the donor site are diseased, there will be no available grafting vessels for bypass surgery. Artificial blood vessels can replace autologous blood vessels as new grafting vessels for arteriovenous fistula or vascular bypass surgery. At present, artificial blood vessels based on polyethylene terephthalate (Polyethylene terephthalate) and expanded polytetrafluoroethylene (Polytetrafluoroethylene) have been successfully used in clinical practice, but their diameter is generally greater than 6 mm. For small-caliber artificial blood vessels with a diameter of less than 6 mm, there are still no available clinical products due to the problem of vascular restenosis.
[0003] Intimal hyperplasia caused by abnormal proliferation of smooth muscle cells is the main cause of restenosis in small-caliber artificial blood vessels. Therefore, it is necessary to develop a small-caliber artificial blood vessel that can inhibit abnormal proliferation of smooth muscle cells.
[0004] In the prior art, some researchers have conducted research on this. For example, the Chinese patent document with publication number CN116271251A discloses a tissue engineering small-caliber artificial blood vessel graft and its preparation method and application. In the invention, the ex vivo vascular substrate is first treated to obtain a complete small-caliber artificial blood vessel stent, and the PDACOF / LY (surface amino-loaded TGF-βR inhibitor LY2157299 covalent organic framework) nanoparticles are covalently bonded to the surface of the small-caliber artificial blood vessel stent using a carbodiimide crosslinker for the first layer of assembly, and then a bifunctional group crosslinker is used to covalently crosslink the small-caliber artificial blood vessel obtained after the first layer of assembly with negatively charged anticoagulant high molecular weight hyaluronic acid and 4-25 disaccharide unit hyaluronic acid for the second layer of assembly, and finally, electrostatic adsorption is used to adhere positively charged endothelial cells to the small-caliber artificial blood vessel obtained after the second layer of assembly, and in vitro cell culture is performed to complete the third layer of assembly to obtain a vascular surface cell-based artificial blood vessel graft. However, the invention uses an ex vivo vascular substrate and the preparation process is relatively complicated.
[0005] The Chinese patent document with publication number CN107213512A discloses a multifunctional small-caliber artificial blood vessel with staggered release and double sustained-release coating and a preparation method thereof. The multifunctional small-caliber artificial blood vessel includes an artificial blood vessel, and a double-layer coating is sprayed on the inner and outer surfaces of the artificial blood vessel. The inner coating of the double-layer coating is a PTX (Paclitaxel) sustained-release PDMS (Polydimethylsiloxane) coating PTX-PDMS, and the outer coating of the double-layer coating is a biodegradable polylactic acid-glycolic acid copolymer nanoparticle sustained-release coating that encapsulates VEGF (vascular endothelial growth factor) gene. However, in the invention, the caliber size of the artificial blood vessel used is unknown, and a specific automatic spraying device is required for preparation. Summary of the invention
[0006] The present invention provides a method for preparing an artificial blood vessel loaded with small molecule interfering RNA, which can solve the problem that the existing small-caliber artificial blood vessels are prone to vascular restenosis due to intimal hyperplasia, and the preparation conditions are mild, and the process is simple and efficient.
[0007] The specific technical solutions adopted are as follows:
[0008] A method for preparing an artificial blood vessel loaded with small molecule interfering RNA comprises the following steps:
[0009] (1) Using electrospinning to prepare a polymer solution into an artificial blood vessel, and preparing a polydopamine coating on the surface of the artificial blood vessel;
[0010] (2) preparing a liposome membrane comprising egg yolk phosphatidylcholine and cationic lipids, obtaining cationic lipid nanoparticles by extrusion, and further co-extruding the macrophage membrane and the cationic lipid nanoparticles to obtain macrophage membrane-modified cationic lipid nanoparticles;
[0011] (3) using a co-extrusion method to compound macrophage membrane-modified cationic lipid nanoparticles and small interfering RNA to prepare macrophage membrane-modified cationic lipid nanoparticles containing small interfering RNA;
[0012] (4) Immersing the artificial blood vessel obtained in step (1) into the solution of macrophage membrane-modified cationic lipid nanoparticles containing small molecule interfering RNA obtained in step (3), allowing it to stand, taking it out and washing it to obtain the artificial blood vessel loaded with small molecule interfering RNA.
[0013] The present invention first prepares a polydopamine coating on the surface of an artificial blood vessel, so that the hydrophilicity of the artificial blood vessel is significantly improved while being negatively charged. Further, cationic lipid nanoparticles modified by macrophage membranes are used to load small molecule interfering RNA, and the small molecule interfering RNA is combined with the artificial blood vessel surface based on the interaction force between charges and hydrogen bonding, so as to prepare an artificial blood vessel loaded with small molecule interfering RNA. The cationic lipid nanoparticles modified by the macrophage membrane can reduce the phagocytosis of small molecule interfering RNA by macrophages, increase the release and expression of small molecule interfering RNA in target vascular smooth muscle cells, and thus inhibit the excessive proliferation of vascular smooth muscle cells. The artificial blood vessel can be clinically used as a vascular substitute in hemodialysis, peripheral vascular replacement, and coronary artery bypass grafting.
[0014] The process parameters of the electrospinning method are: voltage 10-15 kV, polymer solution flow rate 1.6-2.4 mL / h, receiver is a stainless steel iron rod, spinning temperature is 20-30 ° C, relative humidity is 40%-50%, polymer solution concentration is 10-20wt%; the caliber of the artificial blood vessel produced by the electrospinning method is 0.7-6 mm.
[0015] The polymer includes polycaprolactone, polylactic acid-co-glycolic acid, poly-L-lactide-caprolactone, polyurethane or polyglycerol sebacate.
[0016] Preferably, when preparing the polydopamine coating, the artificial blood vessel is immersed in an acetic acid-sodium acetate buffer containing dopamine and sodium periodate for 20-40 min, and then taken out and washed to prepare the polydopamine coating; the pH of the acetic acid-sodium acetate buffer is 5.0-5.5. This method can be used to prepare a super-hydrophilic and negatively charged polydopamine coating, which is conducive to the loading of macrophage membrane-modified cationic lipid nanoparticles containing small molecule interfering RNA in the later stage.
[0017] More preferably, the concentration of dopamine is 1-2 mg / mL, and the concentration of sodium periodate is 2-4 mg / mL.
[0018] Optionally, the cationic lipid is N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP); in the liposome membrane, the mass ratio of egg yolk phosphatidylcholine to the cationic lipid is 2-9:1.
[0019] Preferably, the mass ratio of the macrophage membrane and the cationic lipid nanoparticles during co-extrusion is 1:100-1000.
[0020] Preferably, the small interfering RNA is a small interfering RNA targeting thrombospondin (THBS1-siRNA), and the sequence is 5'-GGAGUGGACUGUAGAUAGU-3'. Further preferably, in order to improve the stability and efficiency of the small interfering RNA, a TT sequence is added to the 3' end.
[0021] Further preferably, the mass ratio of macrophage membrane-modified cationic lipid nanoparticles to small molecule interfering RNA is 20-50:1.
[0022] Preferably, the solution concentration of the macrophage membrane-modified cationic lipid nanoparticles containing small interfering RNA is 0.5-2 mg / mL, and the standing time is 8-36 h.
[0023] The present invention also provides an artificial blood vessel loaded with small molecule interfering RNA, which is prepared by the preparation method of the artificial blood vessel loaded with small molecule interfering RNA.
[0024] The present invention also provides the application of the artificial blood vessel loaded with small molecule interfering RNA in the field of biomedical materials. Specifically, the artificial blood vessel loaded with small molecule interfering RNA can be used clinically as a blood vessel substitute in hemodialysis, peripheral vascular replacement, and coronary artery bypass grafting.
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] (1) The thrombospondin THBS1 is abnormally elevated in artificial blood vessel regenerated vascular smooth muscle cells and damaged smooth muscle cells. The present invention uses a specific method to load THBS1-siRNA onto artificial blood vessels, thereby using THBS1-siRNA to reduce the expression of THBS1 in vascular smooth muscle cells and inhibit excessive proliferation of smooth muscle cells;
[0027] (2) The present invention prepares a polydopamine coating on the surface of an artificial blood vessel, so that the hydrophilicity of the artificial blood vessel is significantly improved, the artificial blood vessel has super hydrophilicity, is negatively charged, has adhesion, and has a strong binding force with cationic lipid nanoparticles modified with macrophage membranes containing small molecule interfering RNA, which is beneficial to the loading of cationic lipid nanoparticles modified with macrophage membranes containing small molecule interfering RNA on the artificial blood vessel;
[0028] (3) The present invention uses cationic lipid nanoparticles modified with macrophage membranes to modify THBS1-siRNA onto the surface of super-hydrophilic and negatively charged PCL artificial blood vessels, which can reduce its phagocytosis by macrophages and increase its release of THBS1-siRNA in vascular smooth muscle cells, thereby reducing the expression of THBS1 in vascular smooth muscle cells and inhibiting the excessive proliferation of vascular smooth muscle cells, thereby preparing a small-caliber artificial blood vessel with the effect of inhibiting vascular intimal hyperplasia. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The figure is a schematic diagram of the preparation of the artificial blood vessel loaded with small molecule interfering RNA.
[0030] Figure 2 (a) is a statistical graph of the encapsulation efficiency of THBS1-siRNA by cationic lipid nanoparticles modified with macrophage membranes in Example 1, (b) is a graph of the degradation experiment of THBS1-siRNA in cationic lipid nanoparticles modified with macrophage membranes containing small interfering RNA in Example 1, (c) is a graph showing the effect of cationic lipid nanoparticles modified with macrophage membranes containing small interfering RNA on THBS1 transcription in Example 1, and (d) is a graph showing the effect of cationic lipid nanoparticles modified with macrophage membranes containing small interfering RNA on the expression of THBS1 at the protein level in Example 1.
[0031] Figure 3 (a) shows the phagocytosis of cationic lipid nanoparticles with / without macrophage membrane modification by vascular smooth muscle cells, (b) shows the phagocytosis of siRNA cationic lipid nanoparticle complexes and macrophage membrane modified cationic lipid nanoparticles containing small interfering RNA by vascular smooth muscle cells, (c) shows the phagocytosis of cationic lipid nanoparticles with / without macrophage membrane modification by macrophages, and (d) shows the phagocytosis of siRNA cationic lipid nanoparticle complexes and macrophage membrane modified cationic lipid nanoparticles containing small interfering RNA by macrophages.
[0032] Figure 4 (a) is a scanning electron micrograph of different artificial blood vessels, (b) is a diagram showing the distribution of vascular smooth muscle cells in different artificial blood vessels, (c) is a diagram showing the quantitative results of adhered vascular smooth muscle cells, and (d) is a diagram showing the quantitative results of the opening area of vascular smooth muscle cells.
[0033] Figure 5 (a) is the expression result of THBS1 of vascular smooth muscle cells on different artificial blood vessels, (b) is the quantitative result of immunofluorescence staining of (a), and (c) is the quantitative result of contraction-related protein expression of vascular smooth muscle cells on different artificial blood vessels.
[0034] Figure 6 These are morphological images and scanning electron microscope images of different artificial blood vessels in Example 1 after being implanted in vivo for 90 days.
[0035] Figure 7 (a) is the H&E staining result of the modified artificial blood vessel 90 days after implantation, (b) is the quantitative result of the neointima, and (c) is the quantitative result of the wall thickness.
[0036] In the accompanying drawings, * indicates p <0.05, ** indicates p <0.01, NS Indicates no statistical difference. DETAILED DESCRIPTION
[0037] The present invention will be further described below in conjunction with the embodiments and drawings. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention.
[0038] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.
[0039] The THBS1-siRNA used in the examples was synthesized by Shanghai Genema Gene Co., Ltd. and had a sequence of 5'-GGAGUGGACUGUAGAUAGU-3' (SEQ ID NO. 1), and also included a TT sequence at the 3' end to improve stability and efficiency.
[0040] Example 1
[0041] (1) Preparation of PCL electrospinning artificial blood vessels
[0042] Polycaprolactone (PCL) particles were dissolved in trifluoroethanol solvent to prepare a 14wt% PCL trifluoroethanol solution. The PCL trifluoroethanol solution was drawn into filaments by electrospinning at a voltage of 12 kV and a flow rate of 2 mL / h and then sprayed onto a stainless steel rod collector. The spinning temperature was 25°C and the relative humidity was around 45%. When the volume of the sprayed liquid reached 600μL, the collection was stopped and the artificial blood vessel was removed from the stainless steel rod. The caliber of the artificial blood vessel was 2 mm.
[0043] (2) Preparation of cationic lipid nanoparticles modified with macrophage membranes
[0044] Egg yolk phosphatidylcholine (PC) and cationic lipid N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP) were dissolved in chloroform at a mass ratio of 4:1, and the chloroform was volatilized under heating and vacuum conditions to form a liposome membrane. Ultrapure water was added, and the mixture was ultrasonically vibrated and passed through an extruder to form cationic lipid nanoparticles Lipid NP. Macrophage membrane MM was extracted from rat peritoneal macrophages, and the cationic lipid nanoparticles and macrophage membrane were co-extruded through an extruder at a mass ratio of 500:1, and the extrusion was repeated 20 times to prepare macrophage membrane-modified cationic lipid nanoparticles Lipid NP@MM.
[0045] (3) Preparation of macrophage membrane-modified cationic lipid nanoparticles containing THBS1-siRNA
[0046] The macrophage membrane modified cationic lipid nanoparticles prepared in step (2) and 5 μM THBS1-siRNA solution were passed through an extruder, the mass ratio of the macrophage membrane modified cationic lipid nanoparticles to THBS1-siRNA was controlled to be 30:1, and the extrusion was repeated 20 times to prepare macrophage membrane modified cationic lipid nanoparticles siRNA+Lipid NP@MM containing THBS1-siRNA.
[0047] (4) Construction of polydopamine (PDA) coating on the surface of PCL artificial blood vessels
[0048] The PCL artificial blood vessel was immersed in acetic acid-sodium acetate buffer (pH 5.2) containing 2 mg / mL dopamine and 2 mg / mL sodium periodate for 30 minutes, taken out, and then washed with ultrapure water to form a PDA coating on the surface of the PCL artificial blood vessel. The above process was repeated 3 times.
[0049] (5) Construction of artificial blood vessels loaded with THBS1-siRNA
[0050] The PCL artificial blood vessel with polydopamine coating prepared in step (4) was immersed in a 1 mg / mL solution of macrophage membrane-modified cationic lipid nanoparticles containing THBS1-siRNA prepared in step (3), left to stand for 24 hours, taken out, and then repeatedly washed with ultrapure water for 3 times to remove the non-adherent nanoparticles, thereby preparing an artificial blood vessel loaded with THBS1-siRNA.
[0051] Example 2
[0052] The preparation method of the artificial blood vessel loaded with small molecule interfering RNA in this example is similar to that in Example 1, the only difference being that the caliber of the artificial blood vessel is 4 mm, and the other processes and parameters are the same.
[0053] Example 3
[0054] The preparation method of the artificial blood vessel loaded with small molecule interfering RNA in this embodiment is similar to that in Example 1, except that the cationic lipid nanoparticles and the macrophage membrane are co-extruded through an extruder at a mass ratio of 200:1, and the other processes and parameters are the same.
[0055] Example 4
[0056] The preparation method of the artificial blood vessel loaded with small molecule interfering RNA in this example is similar to that in Example 1, except that the PCL artificial blood vessel with polydopamine coating prepared in step (4) is immersed in 2 mg / mL macrophage membrane-modified cationic lipid nanoparticle solution containing THBS1-siRNA prepared in step (3), and the other processes and parameters are the same.
[0057] Sample analysis
[0058] Figure 1 The figure is a schematic diagram of the preparation of the artificial blood vessel loaded with small molecule interfering RNA. The artificial blood vessel loaded with small molecule interfering RNA prepared in Example 1 was characterized and its performance tested. The control group was obtained by omitting the corresponding steps on the basis of Example 1. The results are as follows:
[0059] Figure 2 (a) is a statistical graph of the encapsulation efficiency of THBS1-siRNA by cationic lipid nanoparticles modified with macrophage membranes. It can be seen that about 30% of THBS1-siRNA is encapsulated in the cationic lipid nanoparticles Lipid NP@MM modified with macrophage membranes.
[0060] Figure 2 (b) is a degradation experiment diagram of macrophage membrane-modified cationic lipid nanoparticles siRNA+Lipid NP@MM containing THBS1-siRNA. The results show that macrophage membrane-modified cationic lipid nanoparticles can effectively prevent siRNA from being rapidly degraded by serum or RNase.
[0061] Figure 2(c) is a diagram showing the effect of cationic lipid nanoparticles siRNA+Lipid NP@MM modified with macrophage membrane containing THBS1-siRNA on the expression of THBS1 in smooth muscle cells at the transcriptional level. NC+PBS means that negative control disordered siRNA and phosphate buffer were added to the culture medium; siRNA+PBS means that THBS1-siRNA and phosphate buffer were added to the culture medium; NC+RNAiMAX means that negative control disordered siRNA and transfection reagent were added to the culture medium; siRNA+RNAiMAX means that THBS1-siRNA and transfection reagent were added to the culture medium; NC+Lipid NP@MM means that cationic lipid nanoparticles modified with macrophage membrane containing negative control disordered siRNA were added to the culture medium; siRNA+Lipid NP@MM means that cationic lipid nanoparticles modified with macrophage membrane containing THBS1-siRNA were added to the culture medium. The results show that the addition of cationic lipid nanoparticles siRNA+Lipid NP@MM modified with macrophage membrane containing THBS1-siRNA to the culture medium can effectively reduce the transcription of THBS1 in vascular smooth muscle cells.
[0062] Figure 2 (d) is a diagram showing the effect of macrophage membrane-modified cationic lipid nanoparticles containing THBS1-siRNA on the expression of THBS1 at the protein level. The results show that siRNA+Lipid NP@MM can effectively reduce the expression of THBS1 at the protein level in vascular smooth muscle cells.
[0063] Figure 3 (a) shows the phagocytosis of cationic lipid nanoparticles Lipid NP and macrophage membrane-modified cationic lipid nanoparticles Lipid NP@MM by vascular smooth muscle cells; Figure 3 (b) shows the phagocytosis of siRNA cationic lipid nanoparticle Lipid NP complex and macrophage membrane-modified cationic lipid nanoparticles containing THBS1-siRNA by vascular smooth muscle cells. Figure 3 (c) shows the phagocytosis of cationic lipid nanoparticles Lipid NP and macrophage membrane-modified cationic lipid nanoparticles Lipid NP@MM by macrophages; Figure 3 (d) in the figure shows the phagocytosis of siRNA cationic lipid nanoparticle Lipid NP complex and macrophage membrane-modified cationic lipid nanoparticles containing THBS1-siRNA by macrophages. The results show that cationic lipid nanoparticles modified with macrophage membrane can be phagocytosed by vascular smooth muscle cells but not by macrophages.
[0064] Figure 4PCL is an unmodified artificial blood vessel, PCL+siRNA+Lipid NP@MM is an artificial blood vessel modified with cationic lipid nanoparticles modified with macrophage membrane containing THBS1-siRNA only, and PCL+PDA is an artificial blood vessel modified with polydopamine; Figure 4 (a) is a scanning electron microscope image of artificial blood vessels after different modifications. Figure 4 (b) shows the distribution of vascular smooth muscle cells on artificial blood vessels after different modifications. Figure 4 (c) is the quantitative result of adhered vascular smooth muscle cells. Figure 4 (d) in the figure is the quantitative result of the opening area of vascular smooth muscle cells; the results show that polydopamine modification can make the cationic lipid nanoparticles modified with macrophage membrane containing THBS1-siRNA evenly distributed on the artificial blood vessels, and increase the biocompatibility of artificial blood vessels to vascular smooth muscle cells.
[0065] Figure 5 (a) shows the expression results of THBS1 in vascular smooth muscle cells on artificial blood vessels with different modifications. Figure 5 (b) in the figure is the quantitative result of immunofluorescence staining of (a), which shows that polydopamine and cationic lipid nanoparticles modified with macrophage membrane containing THBS1-siRNA can reduce the expression of THBS1 in vascular smooth muscle cells planted on artificial blood vessels. Figure 5 (c) shows the expression levels of THBS1 and contraction-related proteins (aSMA, sM22, CYCLIN D1, FGFR1, EGR1, β-TUBULIN) in vascular smooth muscle cells on different artificial blood vessels. The results show that cationic lipid nanoparticles modified with macrophage membranes containing THBS1-siRNA can reduce the expression of THBS1 in vascular smooth muscle cells implanted on artificial blood vessels and better maintain their contractile phenotype.
[0066] Figure 6 The figures show the morphology and cross-sectional scanning electron micrographs of artificial blood vessels with different modifications after 90 days of implantation in vivo. PCL is an unmodified artificial blood vessel, PCL+siRNA+Lipid NP@MM is an artificial blood vessel modified only with cationic lipid nanoparticles modified with macrophage membrane containing THBS1-siRNA, and PCL+PDA is an artificial blood vessel modified with polydopamine. The results show that the wall thickness of the artificial blood vessel loaded with small molecule interfering RNA is the lowest, and modification with polydopamine and cationic lipid nanoparticles modified with macrophage membrane containing THBS1-siRNA can significantly inhibit the intimal hyperplasia of PCL artificial blood vessels.
[0067] Figure 7(a) shows the H&E staining results of artificial blood vessels with different modifications after 90 days of implantation in vivo, (b) the quantitative results of the new intima, and (c) the quantitative results of the wall thickness. The results show that polydopamine and cationic lipid nanoparticles modified with macrophage membranes containing THBS1-siRNA can significantly inhibit the intimal hyperplasia of PCL artificial blood vessels.
[0068] The embodiments described above provide a detailed description of the technical solutions of the present invention. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, supplements or similar substitutions made within the scope of the principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing an artificial blood vessel loaded with small molecule interfering RNA, characterized in that: The following steps are involved: (1) Using electrospinning to prepare a polymer solution into an artificial blood vessel, and preparing a polydopamine coating on the surface of the artificial blood vessel; (2) preparing a liposome membrane comprising egg yolk phosphatidylcholine and cationic lipids, obtaining cationic lipid nanoparticles by extrusion, and further co-extruding the macrophage membrane and the cationic lipid nanoparticles to obtain macrophage membrane-modified cationic lipid nanoparticles; (3) using a co-extrusion method to compound macrophage membrane-modified cationic lipid nanoparticles and small interfering RNA to prepare macrophage membrane-modified cationic lipid nanoparticles containing small interfering RNA; (4) immersing the artificial blood vessel obtained in step (1) into the solution of macrophage membrane-modified cationic lipid nanoparticles containing small molecule interfering RNA obtained in step (3), allowing the solution to stand, and then removing the solution and washing it to obtain the artificial blood vessel loaded with small molecule interfering RNA; In step (2), the cationic lipid is N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate; in the liposome membrane, the mass ratio of egg yolk phosphatidylcholine to the cationic lipid is 2-9:1; The small molecule interfering RNA is a small molecule interfering RNA targeting thrombospondin, and the sequence is 5'-GGAGUGGACUGUAGAUAGU-3'.
2. The method for preparing an artificial blood vessel loaded with small interfering RNA according to claim 1, characterized in that: The polymer includes polycaprolactone, polylactic acid-co-glycolic acid, poly-L-lactide-caprolactone, polyurethane or polyglycerol sebacate.
3. The method for preparing an artificial blood vessel loaded with small molecule interfering RNA according to claim 1, characterized in that: In step (1), when preparing the polydopamine coating, the artificial blood vessel is immersed in an acetic acid-sodium acetate buffer solution containing dopamine and sodium periodate for 20-40 minutes, and then taken out and washed to obtain the polydopamine coating.
4. The method for preparing an artificial blood vessel loaded with small molecule interfering RNA according to claim 3, characterized in that: The concentration of dopamine is 1-2 mg / mL, and the concentration of sodium periodate is 2-4 mg / mL.
5. The method for preparing an artificial blood vessel loaded with small interfering RNA according to claim 1, characterized in that: The mass ratio of the macrophage membrane and the cationic lipid nanoparticles during co-extrusion is 1:100-1000; and / or the mass ratio of the macrophage membrane-modified cationic lipid nanoparticles and the small molecule interfering RNA is 20-50:
1.
6. The method for preparing an artificial blood vessel loaded with small interfering RNA according to claim 1, characterized in that: In step (4), the concentration of the solution of macrophage membrane-modified cationic lipid nanoparticles containing small interfering RNA is 0.5-2 mg / mL, and the standing time is 8-36 h.
7. An artificial blood vessel loaded with small molecule interfering RNA, characterized in that: The artificial blood vessel is prepared by the preparation method of the artificial blood vessel loaded with small molecule interfering RNA according to any one of claims 1 to 6.
8. Use of the artificial blood vessel loaded with small molecule interfering RNA according to claim 7 in the field of biomedical materials.
